Yoga, an eventual new offering may be required here sometime this spring yes...but they still have plenty of time to deliver fresh material results and get back above $1 per share.
Of interesting note, now that the o/s is most likely around 35M a $1 share price also gets them back to regaining compliance on the NAZ min market cap requirement too.
Regardless, there's no reason right now for anyone to think a new financing offering is imminent and there's still plenty of time for new valuation driving catalysts to arrive to justify a much higher share price.
We still don't know if IPCI completed and submitted PODRAS studies to the FDA as they said they planned on doing sometime in the back half of 2017.
We still don't know if IPCI has in fact launched the oral and nasal studies on their OxyContin NDA candidate so an update on that front could be coming soon.
We still don't know if/when the FDA is finally gonna grant approval on their Pristiq and Lamictal ANDA's. But if 1 or both of those get approved soon that's going to have a positive impact on the valuation metrics that get applied here because both of those generics are already partnered with Mallinkrodt.
And finally, we still don't know if MNK is going to be increasing SeroquelXR sales as contracts with other companies on SeroquelXR expire...and we still don't know if any other partnerships are approaching on the horizon in regards to other ANDA's, Regabatin or PODRAS.
So it's definitely premature for anyone to expect any new offering until at least after IPCI posts their fiscal year end financials next month...and if some of the long anticipated positives finally start arriving there's no reason whatsoever not to expect a much higher share price to begin arriving and renewed market enthusiasm for this stock as 2018 unfolds glty.
News 
Market Data 
Discover 
AI
